Publication:
Diagnostic role and prognostic impact of positron emission tomography/computed tomography in patients treated for uterine corpus cancer

dc.contributor.authorStojiljković, Milica (55217486100)
dc.contributor.authorŠobić-šaranović, Dragana (57202567582)
dc.contributor.authorOdalović, Strahinja (57218390032)
dc.contributor.authorPetrović, Jelena (57207943674)
dc.contributor.authorPopović-Krneta, Marina (57428070900)
dc.contributor.authorVeljković, Miloš (57211281286)
dc.contributor.authorRanković, Nevana (57222052968)
dc.contributor.authorArtiko, Vera (55887737000)
dc.date.accessioned2025-06-12T11:50:18Z
dc.date.available2025-06-12T11:50:18Z
dc.date.issued2024
dc.description.abstractIntroduction/Objective The goal of our research was to evaluate diagnostic and prognostic role of positron emission tomography/computed tomography (PET-CT) in patients previously treated for uterine cancer and compare it to conventional imaging methods (CIM). Methods We analyzed 37 patients examined on PET-CT for follow-up or suspicion of uterine cancer recurrence, and who were previously treated with surgery and/or chemoradiotherapy. All patients underwent CT or magnetic resonance imaging prior to PET-CT, and were followed-up for at least one year. Results PET-CT showed sensitivity, specificity and diagnostic accuracy in uterine cancer relapse detection of 96.3%, 70%, and 89.2%, while those values for CIM were 92.6%, 40%, and 78.4 %, respectively. Correlation of PET-CT and CIM findings was 78% (29/37). In 13 out of 25 true positive patients on CIM, PET-CT found greater number of active sites missed by conventional imaging. Positive findings on PET-CT were associated with shorter progression free survival (p = 0.023, logrank test). Conclusion PET-CT constitutes an important diagnostic method in management of recurrent cancer of uterine corpus, demonstrating high sensitivity and accuracy. In comparison to CIM, PET-CT can discover larger number of active tumor sites, and also shows better specificity. PET-CT positive patients have worse prognosis with shorter progression free survival. © 2024, Serbia Medical Society. All rights reserved.
dc.identifier.urihttps://doi.org/10.2298/SARH230504013S
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85194239342&doi=10.2298%2fSARH230504013S&partnerID=40&md5=9fe5dcc813f48b1cb71da12d34e8e6d0
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/1444
dc.subjectendometrial cancer
dc.subjectfluorodeoxyglucose
dc.subjectprogression free survival
dc.subjectsensitivity
dc.subjectspecificity
dc.subjectuterine sarcoma
dc.titleDiagnostic role and prognostic impact of positron emission tomography/computed tomography in patients treated for uterine corpus cancer
dspace.entity.typePublication

Files